Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy

Liver International

Volumn 35, Issue 11, 2015, Pages 2363-2369

  Lee, Ji Yun ^a   Lim, Sung Hee ^a   Lee, Min Young ^a   Kim, Haesu ^a   Sinn, Dong Hyun ^a   Gwak, Geum Youn ^a   Choi, Moon Seok ^a   Lee, Joon Hyeok ^a   Jung, Chul Won ^a   Jang, Jun Ho ^a   Kim, Won Seog ^a   Kim, Seok Jin ^a   Kim, Kihyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Anti HBc positive; HBsAg negative; Hepatitis B reactivation; Multiple myeloma

Indexed keywords

ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MELPHALAN; TENOFOVIR; THALIDOMIDE; ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER THERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEPATITIS B; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VIRUS REACTIVATION; ADVERSE EFFECTS; AGED; BLOOD; COMPLICATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B VIRUS; KAPLAN MEIER METHOD; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS ACTIVATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84945436648     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12838     Document Type: Article

References (36)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
2. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010; 11: 827-34.
3. Yagci M, Ozkurt ZN, Yegin ZA, et al. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010; 15: 240-4.
4. Liu WP, Zheng W, Song YQ, et al. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. World J Gastroenterol 2014; 20: 5165-70.
5. Yang Y, Du Y, Luo WX, et al. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy. Cancer Chemother Pharmacol 2015; 75: 783-90.
6. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-8.
7. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
8. Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31: 295-300.
9. Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. World J Gastroenterol 2014; 20: 14581-8.
10. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
11. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
12. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
14. Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20: 6262-78.
15. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-9.
16. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
17. Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy. Int J Hematol 2015; ; 101: 398-404.
18. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-80.
19. Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013; 49: 3486-96.
20. Yang JD, Girotra M, Restrepo A, et al. Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance. Ann Hepatol 2014; 13: 461-5.
21. Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report. J Clin Exp Hematop 2012; 52: 67-9.
22. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716-30.
23. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20.
24. Simons A, Shaffer LG, Hastings RJ. Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. Cytogenet Genome Res 2013; 141: 1-6.
25. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32: 3736-43.
26. Mya DH, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012; 23: 421-6.
27. Nolte A, Buhmann R, Emmerich B, et al. Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 108: 415-23.
28. Ashihara E, Shimazaki C, Yamagata N, et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 1994; 13: 377-81.
29. Scheid C, Pettengell R, Ghielmini M, et al. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 15: 901-6.
30. Tong Y, Qian J, Li Y, et al. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007; 82: 403-4.
31. Jones JO, Arvin AM. Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol 2006; 80: 5113-24.
32. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
33. Hussain S, Ahsan S, Bloom RE, et al. Bortezomib induced hepatitis B reactivation. Case Rep Med 2014; 2014: 964082.
34. Goldberg R, Smith E, Bell S, et al. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B. Intern Med J 2013; 43: 835-6.
35. Li J, Huang B, Li Y, et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma 2015; 14: 1-8.
36. Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014; 6: 860-9.